New Strategy Speeds Biliary Atresia Diagnosis in Newborns

Biliary atresia (BA), a rare and rapidly progressive liver disease in newborns, often goes undetected until irreversible damage has occurred. A newly described clinical strategy, detailed in a review published in World Journal of Pediatric Surgery (DOI: 10.1136/wjps-2025-001142), aims to accelerate diagnosis by combining direct or conjugated bilirubin (DB/Bc) measurements with a feeding abdominal ultrasound exam. Researchers from Texas Children's Hospital, Baylor College of Medicine, and Stanford University School of Medicine developed this streamlined pathway to help clinicians identify infants requiring urgent evaluation while reducing unnecessary invasive testing. The approach leverages DB/Bc testing in the newborn nursery and early outpatient visits, guided by tools like BiliScreen.org, and a feeding ultrasound that visualizes key biliary signs without requiring fasting. This dual strategy could significantly shorten the diagnostic window, which is critical since infants treated before 30–45 days of life have better outcomes, yet many are diagnosed after 60 days.

The first step involves measuring DB/Bc levels, which can be elevated within 24–48 hours of birth in infants with BA, even before clinical signs emerge. Primary care providers are advised to test at 2–4 weeks for persistent jaundice, pale stools, or prior high DB/Bc levels, aligning with American Academy of Pediatrics (AAP) guidance. The second step uses a feeding ultrasound to assess maximum echogenicity (MxE) near the right portal vein and the duct at the hilum (DaH). An MxE greater than 4.0 mm or an absent DaH raises concern for BA, prompting definitive evaluation. This method avoids fasting, making follow-up less burdensome, and may reduce reliance on invasive tests requiring anesthesia. The authors emphasize that the pathway is designed to support the full care team—from nursery providers to surgeons—without replacing specialist judgment.

The potential implications are far-reaching. Universal newborn DB/Bc screening could reduce diagnostic delays and address disparities by identifying risk before visual signs are missed. For families, earlier detection means faster treatment decisions and a better chance of preserving the native liver through timely Kasai portoenterostomy. Future studies will need to evaluate implementation and cost-effectiveness across diverse healthcare settings. This innovative workflow represents a practical step toward improving outcomes for infants with biliary atresia, a disease where every day counts.